Last reviewed · How we verify
Lansoprazole (Takepron OD)
Lansoprazole (Takepron OD) is a Proton pump inhibitor (PPI) Small molecule drug developed by National Taiwan University Hospital. It is currently in Phase 3 development for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Lansoprazole (Takepron OD) |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Lansoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. It is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
Key clinical trials
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment (NA)
- Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities. (NA)
- Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori (PHASE4)
- Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD (NA)
- Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin
- Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs
- Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lansoprazole (Takepron OD) CI brief — competitive landscape report
- Lansoprazole (Takepron OD) updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about Lansoprazole (Takepron OD)
What is Lansoprazole (Takepron OD)?
How does Lansoprazole (Takepron OD) work?
What is Lansoprazole (Takepron OD) used for?
Who makes Lansoprazole (Takepron OD)?
What drug class is Lansoprazole (Takepron OD) in?
What development phase is Lansoprazole (Takepron OD) in?
What are the side effects of Lansoprazole (Takepron OD)?
What does Lansoprazole (Takepron OD) target?
Related
- Drug class: All Proton pump inhibitor (PPI) drugs
- Target: All drugs targeting H+/K+-ATPase (proton pump)
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Indication: Drugs for Peptic ulcer disease
- Indication: Drugs for Zollinger-Ellison syndrome
- Compare: Lansoprazole (Takepron OD) vs similar drugs
- Pricing: Lansoprazole (Takepron OD) cost, discount & access